3379 |
Optimal Antithrombotic Treatment in Patients with AF Undergoing PCI |
Freek W.A. Verheugt |
Apr. 25. 17 |
3378 |
Changing Antithrombotic Strategy in Acute Coronary Syndrome |
Jung-Sun Kim |
Apr. 25. 17 |
3377 |
[Invited Case Presentation & Focus Review] TAVI: That Should Not Be too Difficult. |
Horst Sievert |
Apr. 25. 17 |
3376 |
Weigh the Benefit of High Intensity Statin Therapy |
Young Joon Hong |
Apr. 25. 17 |
3375 |
Driving Optimal CV Outcomes: Time Matters |
Young Won Yoon |
Apr. 25. 17 |
3374 |
Bioabsorbable Polymer DES in High Risk Patients |
Chang-Hwan Yoon |
Apr. 25. 17 |
3373 |
[Invited Case Presentation & Focus Review] BVS Scaffold Thrombosis: The Role of OCT |
Evelyn Regar |
Apr. 25. 17 |
3372 |
Magnesium Based Bioresorbable Scaffold Case Presentation |
Vincent On-Hing Kwok |
Apr. 25. 17 |
3371 |
Recent Clinical Evidence of Magnesium Based Bioresorbable Scaffold |
Michael Haude |
Apr. 25. 17 |
3370 |
Magnesium Based Bioresorbable Scaffold- Addressing BRS Safety Concerns |
Georg Daniel Adreas Nollert |
Apr. 25. 17 |